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Introduction 
Hypolipidemia is a decrease in plasma lipoprotein caused 
by primary (genetic) or secondary (acquired) factors. It is 
usually asymptomatic and diagnosed incidentally on routine 
lipid screening. The first report of hypocholesterolemia in 
the medical literature was in 1911 by Chauffard and 
coworkers, in patients with active tuberculosis [1]. Since 
then (about 95 years), only few dozens of studies were 
published in this regard. Unlike hyperlipidemia physicians 
are usually unaware of hypolipidemia, its causes and 
consequences. As the interest in aggressive management 
of hyperlipidemia increases, particularly with the available, 
relatively strong hypolipidemic drugs and the newer and 
probably stronger agents, the following question should be 
answered; how low can we go in serum levels. For the time 
being, it is difficult to give a certain limit for the safest and 
lowest level of serum cholesterol, but knowing the 
complications of hypolipidemia will raise awareness. What 
might appear as a simple mildly reduced serum lipid can be 
an indication of an underlying, serious problem.   A 
systematic search of Pubmed for all the studies in the 
English language as well as the abstracts of publications in 
other languages related to hypolipidemia was undertaken. 
The following words were used in the search: 
hypolipidemia, hypocholesterolemia, 
hypobetalipoproteinemia, and statins. Search results were 
reviewed. 
 
Definition
The terms hypolipidemia, hypocholesterolemia and 
hypobetalipoproteinemia are used interchangeably in the 
literature, and refer to reduced plasma cholesterol. Most 
authors use the total serum cholesterol (TC) to define this 
condition. Yet, there is no consensus about the level below 
which a clinically significant hypocholesterolemia will ensue, 
and each author used a different cut-off value. Even so, 
most of the authors use a cut-off value between 120 mg/dl 
(3.1 mmol/l) and 150m/dl (3.88mmol/l) [2,3,4,5]. However 
some authors use higher levels up to 190mg/dl (4.9mmol/l) 
[6,7] while others use lower values such as 100mg/dl (2.59 
mmol/l) [8,9,10]. 
 
Epidemiology
Hypolipidemia is generally uncommon but secondary 
causes are relatively common compared to the rare primary 
hypolipidemic disorders. The frequency of hypolipidemia 
depends on which plasma cholesterol level is used to define 
the condition. Among the 1,479 men selected from the 
National Health and Nutrition Examination Survey-I, the 
prevalence of hypocholesterolemia (<130mg/dl) was 1.8% 
in whites and 3.6% in blacks [3]. In another survey 
involving 772 firefighters 3.6% of blacks and 2.9% of 
whites were hypocholesterolemic [3]; both surveys 
demonstrate racial differences in the prevalence of 
hypocholesterolemia as it is more likely to be seen in 
blacks. In hospitalized patients the prevalence of 
hypocholesterolemia ranges from 0.5 to 6.2% [5,6,9,11]. 
It is more often seen in males and is linked to increased 
morbidity, longer hospitalization (hence greater cost), 
increased re-hospitalizations rate, and a greater number 
of associated diseases [6]. It is more commonly seen in 
the critically ill and post-operative patients, those with 
septicemia, malignancies, and inflammatory bowel 
disease [11] and is significantly associated with increased 
mortality. 
 
Etiology and classification 
Primary hypolipidemia 
There are 3 rare primary disorders of hypolipidemia in 
which genetic mutations cause an underproduction or 
increased  clearance  of  Low  Density  Lipoproteins       
(LDL) and result in lipid levels low enough to cause 
significant consequences. These conditions are: 
abetalipoproteinemia, hypobetalipoproteinemia and 
chylomicron. 
 
Table-I: Causes of hypolipidemia 
Secondary hypolipidemia 
Multiple mechanisms have been described in different 
diseases and clinical conditions that are found to be 
associated with hypocholesterolemia (Table II). 
 
 
 
 
 
 
 
 
 
 
 
 
Primary disorders  Secondary disorders 
Abetalipoproteinemia  Infection (acute or chronic) 
Hypobetalipoproteinemia Malabsorption  and 
undernutrition 
Chylomicron retention disease  Anemia 
   Chronic inflammation 
   Critical illnesses 
   Malignancies 
   Hyperthyroidism 
   Chronic liver disease 
   Gaucher disease 
   Drug induced: statins 
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Anemia 
Hypocholesterolemia has been described in various types 
of chronic anemia [12-17]. Few studies have suggested 
that such patients have a lower incidence of atherosclerosis 
associated events [12]. Types of anemia that have been 
reported to be associated with hypocholesterolemia 
include: congenital dyserythropoietic anemia [12], 
congenital spherocytosis [12,13], sickle cell anemia [14], 
beta-thalassemia [12,15], aplastic anemia [16] and 
sideroblastic anemia [17]. The exact etiology of 
hypocholesterolemia in anemic patients is not known and 
the data are not sufficient, however several studies 
postulated different mechanisms [12,16-19], and some 
authors even suggest that hypocholesterolemia might be 
the cause rather than the consequence of anemia which is 
explained by the fact that cholesterol deficiency leads to 
rigidity of the erythrocytes [20] making them more prone 
to destruction. Hypocholesterolemia tends to occur in 
patients with chronic anemia and increased erythropoietic 
activity, and it has been suggested that this is due to 
increased cholesterol requirements by the proliferating 
erythroid cells [12]. Some researchers have demonstrated 
hypocholesterolemia in patients with aplastic anemia and 
correlated this with the elevated serum level of 
macrophage colony stimulating factor (M-CSF), which is 
known to have cholesterol-lowering activity, and they found 
that pretreatment total serum cholesterol and triglyceride 
levels nicely correlate with the counts of hemopoietic cells 
in the bone marrow. They concluded that low serum lipids 
suggest severe bone marrow failure in these patients and 
can help to predict the therapeutic response of each case 
of aplastic anemia [16]. Other researchers demonstrated a 
significant increase in serum cholesterol following 
splenectomy in patients with hypersplenism and 
preoperative hypocholesterolemia. They suggest a possible 
role of the spleen in lipid metabolism in these patients [19]. 
Bjerve et al reported a case of sideroblastic anemia and 
hypocholesterolemia due to autoantibodies against LDL 
causing an increased LDL catabolism [17]. Another animal 
study suggested that hypocholesterolemia in anemic mice is 
related to a decreased in vivo hepatic cholesterol synthesis 
[18]. 
 
Hyperthyroidism 
Thyroid disorders are known to affect lipid metabolism 
hence thyroid dysfunction may result in changes in the 
composition and transport of lipoproteins [21]. Both overt 
and subclinical hyperthyroidism is associated with reduced 
serum levels of TC, LDL and high density lipoprotein (HDL) 
[21,22]. Hyperthyroidism can also be the underlying cause 
of unexplained improvement of hyperlipidemia [21]. These 
hypolipidemic changes in hyperthyroidism are explained by 
various effects of thyroid hormones on the lipoprotein 
metabolism. Despite the increased hepatic de novo 
cholesterol synthesis in hyperthyroid states due to 
augmentation of HMG-CoA reductase activity, levels of total 
and LDL cholesterol, are likely to diminish in patients with 
hyperthyroidism due to enhanced LDL receptor-mediated 
catabolism of LDL particles [21,22]  and increased bile 
excretion of cholesterol [21]. Moreover, the triiodothyronine 
(T3) enhances the gene expression of the LDL receptor and 
hence the receptor activity [21]. Thyroid hormones also 
stimulate the enzyme lipoprotein lipase (LPL), which 
catabolizes the triglyceride-rich lipoproteins [21]. The end 
result of all previous changes, is reduction in serum level of 
TC, LDL and HDL. However triglyceride levels remain 
unchanged [21], while the effect on lipoprotein (a) is still 
controversial, because both decrease or no changes have 
been reported [21]. 
 
Table-II: mechanisms of secondary hypocholesterolemia 
Critical illness 
Total cholesterol levels drop at the onset of acute 
illness and return to normal during recovery [23,24]. 
Multiple mechanisms influence hypocholesterolemia in 
critically ill patients and these include: downregulation of 
hepatic synthesis [25], probably due to decreased 
production of cholesterol precursors particularly 
lanosterol and lathosterol [26], loss of apoproteins in 
burns [27], and increased cholesterol catabolism [25,28]. 
Low cholesterol concentrations associated with high 
levels of cytokines such as interleukin (IL)-6 and IL-10 
[28], Hypocholesterolemia have  been reported in 
patients with acute severe pyelonephritis [29], major 
trauma [24,26], those with multiple organ dysfunction 
syndrome [25], burns [27], sepsis [30], and in patients 
undergoing surgical interventions [31] . More 
importantly, hypocholesterolemia is not only a marker for 
the disease severity but it may also predispose critically ill 
patients to sepsis and adrenal failure, and may carry a 
significantly increased risk of mortality. [23,28,30,32]. In 
meningococcal septicemia, Vermont et al demonstrated 
that total cholesterol, HDL, and LDL levels on admission 
correlate inversely with disease severity and cortisol level 
[30]. The severity of hypocholesterolemia in sepsis is 
directly related to the severity of acute phase response 
[33]. In patients with major trauma Dunham et al 
demonstrated that hypocholesterolemia improves with 
recovery from acute illness but continues with 
development of organ failure or occurrence of infection 
[24]. 
 
In chronic illness: 
 
  - chronic exposure to IL-6 , IL-10 and TNF 
  - undernutrition due to anorexia   
In critically ill patients: 
 - downregulation of hepatic synthesis, due to decreased 
production of     cholesterol precursors.  
- dilutional effects of fluid resuscitation 
- loss of apoproteins in burns 
- increased cholesterol catabolism 
In cancer patients: 
- elevated LDL receptor activity in malignant cells 
- undernutrition due to anorexia  
- effect of TNF 
In anemia: 
- increased cholesterol requirements by the proliferating 
erythoid cells 
- elevated serum level of macrophage colony stimulating factor 
(M-CSF) 
- hypersplenism 
- autoantibodies against LDL causing an increased LDL 
catabolism 
In thyrotoxicosis: 
- enhanced LDL receptor-mediated catabolism of LDL particles 
- increased bile excretion of cholesterol 
- increased lipoprotein lipase, which catabolizes the 
triglyceride-rich lipoproteins 
- increased LDL-receptor activity 
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Malignancy 
Several studies suggest an inverse relationship between 
serum cholesterol level and cancer mortality in patients 
with hematological and solid organ malignancies [34-39]. 
Elevated LDL receptor activity in malignant cells may be a 
contributing factor to hypocholesterolemia in some cancer 
patients [38]. The evidence relating hypocholesterolemia to 
increased risk of cancer is controversial. In a large 
prospective study of Japanese-American men followed for 
> 20 years, hypocholesterolemia was associated with 
increased risk of colonic cancer development; this 
relationship becomes stronger as the site of cancer shifts 
from the left to the right colon. The authors suggest that 
the preclinical effects of occult colonic cancer is responsible 
for this inverse relationship, but these effects do not 
explain why the association with hypolipidemia was 
stronger in patients who were later diagnosed with right-
sided colon cancer [39]. Swanson et al also thought that 
hypocholesterolemia might be a predisposing factor for 
endometrial cancer [37]. In a large Japanese study of 9216 
persons, hypocholesterolemia was significantly associated 
with an increased risk of liver cancer [40]. Moreover, 
several animal experiments have found that statins are 
carcinogenic at blood concentrations similar to those 
achieved by doses commonly used to treat hyperlipidemia, 
the carcinogenicity may be due to the effects of statins on 
cholesterol [41]. Furthermore, some human studies also 
connected the use of lipid lowering drugs to cancer 
development. The cholesterol and recurrent events trial 
(CARE), showed a significant increase in breast cancer, 
particularly recurrences [42], while the trial of Pravastatin 
in elderly individuals at risk of vascular disease (PROSPER), 
concluded that the benefit from fewer cardiovascular 
deaths was counterbalanced by the significant increase in 
cancer mortality [43]. Although several recent studies give 
reassuring evidences regarding the safety of statins with 
respect to carcinogenicity up to 10 years [44] but this 
period remains relatively short compared with the medically 
accepted latency period for cancer of 20 years [45]. In 
conclusion, evidence regarding the carcinogenicity of 
hypocholesterolemia from clinical studies in humans is 
inconclusive because of conflicting results and 
unsatisfactory duration of follow-up. The available evidence 
does not significantly support a direct cause-effect 
relationship between hypocholesterolemia and cancer [46], 
rather, the data suggest that low cholesterol levels may 
serve as a "marker," or prognostic indicator of the disease 
[47]. 
 
Malabsorption 
Since dietary fats constitute the exogenous source of 
body lipids,  undernutrition or fat malabsorption can lead to 
hypolipidemia. Brar et al demonstrated that celiac disease is 
associated with hypocholesterolemia and a gluten-free diet 
will result in rising of total cholesterol and HDL [48]. In 
patients with chronic pancreatitis, cholesterol absorption is 
markedly reduced primarily due to reduced intestinal 
lipolysis [49]. Bile acid malabsorption was also named as an 
additional factor in the development of hypocholesterolemia 
in patients with chronic pancreatitis [50]. Malabsorption is a 
common finding in patients with acquired immunodeficiency 
syndrome (AIDS) and fat malabsorption could be a 
contributing factor to the disease associated 
hypocholesterolemia. The pathogenesis of malabsorption in 
AIDS patients is multifactorial including primary enterocyte 
injury and exudative enteropathy [51]. 
 
Infection 
Acute and chronic bacterial, viral, and parasitic 
infections all might induce hypocholesterolemia due to 
the chronic effect of proinflammatory cytokines on 
lipoprotein metabolism. In 1911, Chauffard et al were the 
first to report hypocholesterolemia in patients with 
tuberculosis. Since then, transient hypocholesterolemia 
and hypertriglyceridemia were frequently observed 
during the acute phase of bacterial infections [52]. In 
1920, Kipp noted an association between the degree of 
hypocholesterolemia and the severity of infection [1]. 
These changes are mediated by different cytokines as IL-
1 and tumor necrosis factor-alpha (TNF) which are 
involved in the acute phase response during sepsis [52]. 
In critically ill patients, decreasing cholesterol levels 
suggest the development of infection. Some authors 
believe that hypocholesterolemia is a more sensitive 
marker for the onset of infection than leukocytosis [24]. 
Moreover, hypocholesterolemia was significantly 
correlated with the intensity of the acute phase 
responses during sepsis (as C-reactive protein level) [52]. 
Since parasites need to feed on host cholesterol for a 
successful infection [3], theoretically parasitic infestation 
might cause low plasma cholesterol. Several authors 
have shown that hypocholesterolemia has the strongest 
positive predictive value (96%) of the biological 
parameters for malaria diagnosis, [53]. Visceral 
lieshmaniasis also has been reported to cause 
hypocholesterolemia [54]. Human immune deficiency 
virus (HIV) is associated with hypocholesterolemia during 
the asymptomatic phase and is associated with specific 
alterations in immune function, suggesting that 
hypocholesterolemia may be a useful marker of disease 
progression [4,55]. Hepatitis-C virus (HCV) is associated 
with significantly lower cholesterol levels (TC, LDL and 
HDL) when compared with those of normal subjects. 
Levels of apolipoprotein B (apoB) correlate negatively 
with HCV viral load and this finding is more pronounced 
in patients infected with HCV genotype 3 [56,57]. In a 
Japanese study, infection with genotype 1b was also 
associated with hypocholesterolemia [58]. It was 
postulated that hypobetalipoproteinemia associated with 
HCV is mediated by HCV core protein, which down-
regulates triglyceride metabolism, leading to steatosis 
[59]. Clinically,hypocholesterolemia in genotype 3 is 
associated with a more severe steatosis, and higher 
grades of fibrosis pointing out a more aggressive disease 
[60]. It also increases the risk of hepatocellular 
carcinoma [61]. From the previous studies one can 
suggest that the presence of acquired ApoB deficiency in 
HCV-infected patients may be used as an indication for 
treatment of HCV as it is likely to be associated with a 
more progressive disease. 
 
 
Chronic liver disease 
Because hepatocytes are the most active site of lipid 
metabolism, hypolipidemia is frequently observed in 
severe chronic hepatic insufficiency [8]. A low serum 
cholesterol level is associated with a higher mortality rate 
in patients with liver cirrhosis [8,62]. Advanced chronic 
liver disease can cause a reduction in  apolipoprotein A 
and apolipoprotein B levels. Isolated deficiency of 
apolipoprotein B indicates abetalipoproteinemia or 
familial hypobetalipoproteinemia; which can result in liver 
involvement in the form of elevated transaminases, fatty 
liver and cirrhosis, while deficiency of both apolipoprotein 
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A and apolipoprotein B is a manifestation of advanced 
chronic liver disease regardless of the etiology [63]. 
 
Chronic inflammation 
Changes in plasma lipid levels are a well known 
phenomenon in the acute phase response to inflammation. 
Chronic inflammation also can produce hypocholesterolemia 
due to the chronic effect of proinflammatory cytokines on 
lipoprotein metabolism. Ettinger et al demonstrated that 
chronic IL-6 injection causes acquired hypocholesterolemia 
in nonhuman primates [64]. Bologa et al found a significant 
relationship between TNF and IL-6 and the degree of 
hypolipoproteinemia in hemodialysis patients [65]. Ripollés 
et al have demonstrated that serum cholesterol was 
significantly lower in patients with active inflammatory 
bowel disease than in the control group [66]. 
Hypocholesterolemia also has been reported in patients 
with rheumatoid disorders [67]. Moreover, the anorexia 
that accompanies the chronic inflammatory disorders may 
contribute to the hypolipidemic effect of the 
proinflammatory cytokines in producing hypolipidemia in 
these conditions. 
 
 
Consequences of hypolipidemia 
1- Effects on plasma membrane 
Since about 44% of the human cell membrane is 
composed of lipids, they serve as a major structural 
component.  Cell membranes are absolutely essential for 
the cell survival as well as for biological functions [68]. It is 
not known how very low plasma cholesterol levels would 
affect membrane composition and function but some 
indirect evidence might  shed some  light on this issue. 
Acanthocytes are dense, contracted red blood cells with 
several irregularly spaced thorny projections on the surface 
due to abnormal membrane fluidity. Acanthocytosis is a 
known clinical feature of abetalipoproteinemia and was also 
reported to be associated with hypolipidemia in celiac 
disease. In the later case acanthocytes disappeared two 
weeks after initiation of gluten free diet [69]. 
Acanthocytosis was also reported with 
hypobetalipoproteinemia in advanced chronic liver disease 
[63].The exact mechanism of formation of acanthocytes is 
unclear, but reversal of the usual phosphatidylcholine-
sphingomyelin ratio is considered to be a possible 
mechanism [70]. In a recent animal study, the 
hypolipidemic agent Atorvastatin caused significantly lower 
cholesterol and higher phospholipid content of red blood 
cell membrane, thus decreasing the cholesterol to 
phospholipid ratio. Although these structural changes were 
not associated with any obvious adverse rheological 
alterations, but they show that hypolipidemia may be 
associated with cell membrane lipid changes [71]. 
 
 2- Intracerebral hemorrhage (ICH) 
Intracranial hemorrhage accounts for approximately 10% 
of all strokes, and carries a significantly high morbidity and 
mortality as the 30-day fatality rate reaches up to 50% 
[72]. Several studies have demonstrated that low 
cholesterol is a risk factor for ICH [73-75]. Others have 
reported that hypercholesterolemia is protective against 
ICH [76-78]. Iribarren et al [74] described the association 
between low serum cholesterol level and cerebral 
hemorrhage in elderly men. In another study of young 
patients hypocholesterolemia (</=160mg/dl) was found  
in 35% of the patients with ICH compared to only 13% 
having hypertension [7].  
Hypocholesterolemia was more common in ICH 
patients aged < 20 years and in those with cryptogenic 
ICH [7]. Other authors have mentioned 
hypocholesterolemia <160mg/dl (4.14 mmol/l) as a 
contributing risk factor for Hypolipidemia  intracerebral 
hemorrhage in previously healthy people [75].The causal 
relationship is unclear;  however, some investigators 
have proposed that the interaction of high diastolic blood  
pressure and low cholesterol levels weakens the 
endothelium of the intracerebral arteries [75], while 
another study reported platelet hypoactivity is associated 
with hypocholesterolemia [79], therefore affected 
patients may be more prone to bleeding.  
 
3- Adrenal failure 
Cholesterol molecules are the precursors for adrenal 
steroid hormones. The adrenal gland requires a 
continuous supplement of cholesterol for the biosynthesis 
of adrenal corticosteroids, which can be supplied by LDL 
receptor-mediated uptake or through local synthesis [80]. 
Thus, at least theoretically; hypocholesterolemia will be 
associated with hypocortisolemia, and during stress 
cortisol production may not be high enough to protect 
against the cell damage. Hence critically ill patients will 
be predisposed to adrenal failure [23,30,81]. Although 
few human and animal studies support this hypothesis 
[30,81], several authors have shown that in reality this 
does not happen [80, 82,83]. Animal studies of the 
hypolipidemic drug Nafenopin have shown that despite 
significant lowering of serum cholesterol levels, this failed 
to alter blood corticosterone [82] and aldosterone [83] 
concentrations. This is probably because of the increased 
endogenous cholesterol synthesis as a result of 
compensatory smooth endoplasmic reticulum 
hypertrophy [82,83]. Furthermore, one study of adult 
patients receiving 80 mg of the potent HMG CoA 
reductase inhibitor Simvastatin for two months showed 
that despite a 36%, reduction in total cholesterol level, 
there was no adverse  effect on ACTH-stimulated adrenal 
corticosteroid production [80]. In summary; the available 
evidence is insufficient to support or refute the 
hypothesis that hypocholesterolemia can lead to adrenal 
failure. 
 
4- Sepsis 
Hypocholesterolemia in healthy men is reported to be 
associated with significantly fewer circulating 
lymphocytes, total T cells, and CD8+ cells [84], thus the 
host immunity will be altered and the patient may be 
prone to infection. Harris et al reported that lipoproteins 
bind to and neutralize bacterial endotoxin 
lipopolysaccharide (LPS) [85]. LPS binds to LPS binding 
protein [86], activating the cell surface CD14 receptor 
[87] which stimulates the release of several 
proinflammatory cytokines, including TNF, IL-1, and IL-6 
[88]. If LPS binds to lipoproteins, then cytokine release is 
decreased [89]. It is assumed that hypolipidemia impairs 
the LPS neutralization, hence predisposing to more 
severe inflammation. Recently Kitchens et al [90] 
demonstrated that despite hypocholesterolemia, 
circulating lipoproteins maintain their ability to bind and 
neutralize LPS. However in spite of this recent 
contradiction this issue remains unsolved as evidence 
remains inconclusive. Several authors report that 
hypocholesterolemia may be a predisposing factor to 
sepsis in the critically ill patient [23,30]. A significant 
relationship has been observed between preoperative 
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hypocholesterolemia and incidence of postoperative septic 
complications. Leardi et al reported that the highest 
incidence of postoperative septic complications is seen in 
patients with cholesterol levels below 105 mg/dl [10]. 
Moreover, a very low level of cholesterol is also considered 
to be a prognostic factor during infection, predicting an 
unfavorable outcome in elderly patients [52]. 
Hypocholesterolemia is the most frequently observed 
laboratory finding in fatal cases of pneumonia in the elderly 
[91], in a study conducted at a nursing home; 
hypocholesterolemia was the only admission feature 
associated with death due to bacteremia [2]. Pacelli et al 
reported hypocholesterolemia as an independent predictor 
of death in patients with intra-abdominal infection [92]. In 
neutropenic patients with fever, non-survivors had 
significantly lower serum cholesterol levels compared to 
survivors [93]. From these whole data one can conclude 
that hypocholesterolemia is a risk factor for infection in 
certain conditions as well as a prognostic indicator during 
sepsis. 
 
5 - Disease mortality 
Studies suggest that lipoproteins play a role in the 
binding and neutralization of endotoxins [85]. 
Epidemiologic studies have identified a relationship 
between hypocholesterolemia (< 130 mg/dL) and increased 
mortality from all causes [14]. Crook et al stated that, in 
hospitalized patients the lower the plasma cholesterol the 
higher the mortality, and they demonstrated an increase in 
the mortality rate from 39% to 71% as plasma cholesterol 
dropped from < 77.2mg/dl (2mmol/dl) to < 58mg/dl (1.5 
mmol/l) [11]. A low baseline serum cholesterol level is 
associated with higher mortality rates in patients with liver 
cirrhosis. There is a significant relationship and increased 
risk of mortality in patients with HIV and HCV co-infections 
[62]. Hypocholesterolemia is also associated with increased 
mortality in patients with tuberculosis [94]. Several 
epidemiological studies suggest an inverse relationship 
between serum cholesterol levels and cancer mortality [34]. 
Following a severe trauma, dying patients appear to have 
progressive hypocholesterolemia [24]. In conclusion, 
hypocholesterolemia has a statistically significant 
relationship to mortality in the critically ill patient and is an 
independent predictor of mortality in this group. 
 
The role of lipid lowering drugs 
Lipid lowering drugs, particularly statins, are being more 
widely used to reduce the cardiovascular mortality. Recent 
studies show that cardiovascular risk reduction is 
proportional to the level of reduction of LDL. Therefore the 
American National Cholesterol Education Program 
recommends a more aggressive lipid lowering strategy for 
high risk patients with cardiovascular disease. This means 
that LDL should be < 70mg/dl (1.81 mmol/l). Although 
cholesterol lowering to this degree is more cardioprotective 
in high risk patients, other possible complications may 
neutralize or even outweigh this benefit. For example; 
hypocholesterolemia was associated with increased risk of 
colorectal cancer [36], endometrial cancer [37], and liver 
cancer [40]. Furthermore, some other studies directly link 
the use of lipid lowering drugs to cancer development. The 
CARE trial, showed a significant increase in breast cancer 
[42], while the trial of Pravastatin in elderly individuals at 
risk of vascular disease (PROSPER) concluded that the 
significant increase in cancer mortality counterbalanced the 
benefit of fewer cardiovascular deaths [43]. Moreover; high 
cholesterol has been found to be protective against intra 
cerebral hemorrhage [76-78], therefore lipid-lowering 
medications may increase the risk of ICH (at least 
theoretically), and several studies have demonstrated 
that hypocholesterolemia is a risk factor for ICH [73-75]. 
Considering this evidence, one should be concerned 
about the potential deleterious effects of the drug-
induced hypolipidemia. We should evaluate individual 
cases carefully in light of current strategies for aggressive 
hyperlipidemia  treatment.   
 
Conclusion
Hypolipidemia is a common disorder affecting about 2 - 
3% of apparently healthy individuals and up to 6% of 
hospitalized patients. It might be a marker for an 
underlying, serious problem. Unexplained hypolipidemia 
should always be investigated for a possible cause. 
Several clinical conditions as well as lipid lowering drugs 
may result in clinically significant hypolipidemia. The 
evidence regarding the carcinogenicity of 
hypocholesterolemia from clinical studies in humans is 
inconclusive. The available data suggest that low 
cholesterol levels may serve as a prognostic indicator in 
cancer patients. Low cholesterol is a possible risk factor 
for ICH. Hypocholesterolemia is also a predisposing factor 
for infection in certain conditions as well as a prognostic 
indicator during sepsis. There is a positive relationship 
between low total serum cholesterol levels, and increased 
mortality from all causes particularly in critically ill 
patients. Hypolipidemia may predispose the critically ill 
patient to sepsis and adrenal failure and may carry a 
significantly  increased  risk  of  mortality.                 
Currently, as we focus on aggressive management of 
hyperlipidemia we should at least keep an eye on the 
possible complications of drug-induced hypolipidemia. 
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